Save time and jump to the most important pieces.
SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13D - Oruka Therapeutics, Inc. (0000907654) (Subject)
SC 13G - ARCA biopharma, Inc. (0000907654) (Subject)
4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with
WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
425 - ARCA biopharma, Inc. (0000907654) (Subject)
WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced completion of the merger with Oruka Therapeutics, Inc. ("Oruka") following ARCA's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders on August 22, 2024. ARCA following the merger is referred to herein as the "combined company." As previously announced, the combined company will effect a reverse stock split of its common stock subsequent to the merger. Thomas A. Keuer, President of ARCA said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for the merger with
WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced an update to the previously announced final amount of the special cash dividend (the "Special Dividend"), which will now equal $1.613 per share of ARCA's common stock, payable on August 28, 2024, to ARCA's stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA's Board of Directors on August 16, 2024, in connection with the previously announced merger (the "Merger") with Oruka Therapeutics, Inc. ("Oruka"), pursuant to the Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the "Merger Agreement"). The exact amount of the Special
WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO) ("ARCA") today announced that its Board of Directors (the "Board") has approved a reverse stock split of ARCA's common stock at a ratio of 1-for-12. ARCA's common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol "ORKA" following the anticipated closing of the merger with Oruka Therapeutics, Inc. (the "Merger"), with a new CUSIP number 687604108 and ISIN number US6876041087. The reverse stock split was approved by ARCA's stockholders at ARCA's special meeting of
The Dow Jones index closed higher by more than 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. ARCA biopharma The Trade: ARCA biopharma, Inc. (NASDAQ:ABIO) 10% owner Janus Henderson Biotech Innovation Master Fund Ltd bought a total of 408,777 shares at an average price of $3.49. To acquire these shares, it cost around $1.4 million. W
Gainers Calidi Biotherapeutics (AMEX:CLDI) shares rose 29.7% to $0.25 during Monday's pre-market session. The market value of their outstanding shares is at $16.0 million. Entero Therapeutics (NASDAQ:ENTO) shares rose 22.41% to $2.99. The company's market cap stands at $8.2 million. TransCode Therapeutics (NASDAQ:RNAZ) stock increased by 19.09% to $1.31. The company's market cap stands at $8.6 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 15.3% to $0.47. The market value of their outstanding shares is at $33.2 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares moved upwards by 15.12% to $0.78. The company's market cap stands at $11.6 million. Co-Diagnostics (NASDAQ:
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 70.4% to $3.51 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 21.72% to $4.38. The company's market cap stands at $144.0 million. Structure Therapeutics (NASDAQ:GPCR) shares moved upwards by 19.23% to $40.78. The company's market cap stands at $1.9 billion. NewGenIvf Group (NASDAQ:NIVF) stock rose 16.78% to $1.6. The company's market cap stands at $16.2 million. Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 16.6% to $14.61. The market value of their outstanding shares is at $629.9 million. ARCA biopharma (NAS
ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), (the "Company") a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alterna